Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Zafgen Inc    ZFGN

ZAFGEN INC (ZFGN)
Mes dernières consult.
Most popular
Report
End-of-day quote. End-of-day quote  - 12/11
3.88 USD   -1.40%
11/08 ZAFGEN, INC. (N : ZFGN) Files An 8-K Results of Operations and Finan..
11/07 ZAFGEN : reports 3Q loss
11/07 ZAFGEN : Reports Third Quarter 2017 Financial Results
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/05/2017 12/06/2017 12/07/2017 12/08/2017 12/11/2017 Date
3.85(c) 3.8(c) 3.85(c) 3.935(c) 3.88(c) Last
38 123 80 818 123 723 63 152 101 103 Volume
-0.52% -1.30% +1.32% +2.21% -1.40% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -55,0 M
Net income 2017 -54,4 M
Finance 2017 78,0 M
Yield 2017 -
Sales 2018 -
EBIT 2018 -67,6 M
Net income 2018 -67,0 M
Finance 2018 123 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 0
EV / Sales2018 0
Capitalization 107 M
More Financials
Company
Zafgen, Inc. is a biopharmaceutical company, which is engaged in the development of anti-obesity therapeutics that restores normal fat metabolism and regulatory pathways.Its product: Beloranib, which is under phase 2 clinical development as a treatment for obesity and hyperphagia in Prader-Willi... 
More about the company
Latest news on ZAFGEN INC
11/21 ZAFGEN : New Clinical Trials and Studies Findings from Zafgen, Inc. Described (E..
11/08 ZAFGEN, INC. (NASDAQ : ZFGN) Files An 8-K Results of Operations and Financial Co..
11/07 ZAFGEN : reports 3Q loss
11/07 ZAFGEN : Management's Discussion and Analysis of Financial Condition and Results..
11/07 ZAFGEN, INC. : Results of Operations and Financial Condition, Financial Statemen..
11/07 ZAFGEN : Reports Third Quarter 2017 Financial Results
10/16 ZAFGEN : Reports Inducement Grant under NASDAQ Listing Rule 5635
10/12 ZAFGEN, INC. (NASDAQ : ZFGN) Files An 8-K Departure of Directors or Certain Offi..
10/12 ZAFGEN, INC. : Change in Directors or Principal Officers, Other Events, Financia..
10/12 Zafgen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
More news
Sector news : Bio Therapeutic Drugs
10:43a M&A dominates Europe share trading as oil leads gains
12/09 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/20 Can Rhythm Pharmaceuticals Succeed Where Others Have Failed?
11/07 Zafgen beats by $0.12
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
10/12 Midday Gainers / Losers
10/12 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
Chart ZAFGEN INC
Duration : Period :
Zafgen Inc Technical Analysis Chart | ZFGN | US98885E1038 | 4-Traders
Technical analysis trends ZAFGEN INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 6,67 $
Spread / Average Target 72%
EPS Revisions
Managers
NameTitle
Jeffrey S. Hatfield Chief Executive Officer & Director
Thomas E. Hughes President, Chief Scientific Officer & Director
Peter Barrett Chairman
Patricia L. Allen CFO, Treasurer & Principal Accounting Officer
Dennis D. Kim Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ZAFGEN INC21.07%107
GILEAD SCIENCES1.55%99 094
REGENERON PHARMACEUTICALS1.78%40 969
VERTEX PHARMACEUTICALS88.38%35 831
GENMAB1.79%11 452
BLUEBIRD BIO INC172.12%9 249